Difference between revisions of "Etoposide (Vepesid)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 1: Line 1:
 +
Also known as VP-16.
 +
 
==General information==
 
==General information==
Class/mechanism: <ref name="insert">[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/etoposide .pdf Etoposide (Vepesid) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Topoisomerase inhibitor.  Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals.  Causes the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.<ref name="insert">[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/etoposide.pdf Etoposide (Vepesid) package insert (locally hosted backup)]</ref>
<br>Route: TBD
+
<br>Route: IV
<br>Extravasation: TBD
+
<br>Extravasation: [[irritant]]
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.  
Line 8: Line 10:
 
==Patient drug information==
 
==Patient drug information==
 
*[http://chemocare.com/bio/etoposide.asp Etoposide (Vepesid) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/etoposide.asp Etoposide (Vepesid) patient drug information (Chemocare)]</ref>
 
*[http://chemocare.com/bio/etoposide.asp Etoposide (Vepesid) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/etoposide.asp Etoposide (Vepesid) patient drug information (Chemocare)]</ref>
*[http://www.uptodate.com/contents/etoposide -patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/etoposide -patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]</ref>
+
*[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]</ref>
  
 
==References==
 
==References==
 
<references/>
 
<references/>

Revision as of 03:46, 14 January 2012

Also known as VP-16.

General information

Class/mechanism: Topoisomerase inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].

Patient drug information

References